Choroidal neovascularisation (CNV) is a well-known complication of angioid streaks (AS). It affects 42-86% of patients and if untreated can result in significant vision loss. 1 Treatment options have included laser photocoagulation and photodynamic therapy; 1,2 with the advent of anti-vascular endothelial growth factor (VEGF) therapies, off-label anti-VEGF has become the treatment of choice and both bevacizumab and ranibizumab have been shown to be effective. [1] [2] [3] We describe the off-label use of 2 mg intravitreal aflibercept in two patients as primary treatment for AS-associated CNV (AS-CNV).
spectral-domain optical coherence tomography (SD-OCT) confirmed the diagnosis (Figures 1c-f ) and she was started on a pro re nata (PRN) off-label aflibercept regimen. VA was 20/20 after a single injection and at 12-months followup there were no signs of recurrence (Figures 1g and h ).
The second case relates to a 56-year-old male presenting with right eye (OD) reduced vision and known OS amblyopia. VA was 20/200 OD and 20/40 OS. Fundoscopy, SD-OCT and FA revealed bilateral AS (Figures 2a and b) and a predominantly classic CNV OD (Figures 2a and c-e) . He was started on a 3+PRN off-label aflibercept regimen. VA increased to 20/50 after the loading dose and at 9 months follow-up there was no need for further intervention (Figure 2f ).
Comment
The advent of anti-VEGF agents to treat age-related macular degeneration has encouraged the use of these therapies for CNV of other causes. 3 To the best of our knowledge this is the first report to describe the clinical benefit of aflibercept for AS-CNV. Moreover, as the one of the major difficulties in treating CNV secondary to AS is recurrence, 2 it may be that aflibercept offers an additional benefit over other anti-VEGF agents as it has a higher affinity for VEGF-A as well as the ability to bind VEGF-B and placental growth factor, resulting in a more effective inhibition of the pathological angiogenic process. 4, 5 Further longitudinal studies with a larger cohort of patients are required to verify this hypothesis.
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We read with interest the article by Ho et al 1 describing the factors influencing the treatment outcomes for polypoidal choroidal vasculopathy (PCV) following combination photodynamic therapy and intravitreal ranibizumab injections. This study highlights the key role of indocyanine green angiography (ICGA) in the diagnosis and management of PCV. [2] [3] [4] In addition to the clinical and angiographic features described, it is also important to consider insights from studies that classified PCV into various subtypes. It has been suggested that PCV may not be a single disease entity, but may consist of different subtypes that influence the longterm prognosis. In a study of 107 consecutive patients with PCV, three subtypes of PCV were identified on the basis of the features seen on ICGA and fluorescein angiography. 2 The PCV subtype significantly affected the visual outcome at 5 years. In our series, 21.5% of patients experienced ≥ 0.3 LogMAR unit decrease in visual acuity at 1 year. However, the rates of visual loss differed significantly among the three subtypes: 0% for type A PCV, 8.7% for type B, and 35.3% for type C (P = 0.001). 2 A similar pattern was observed over the subsequent 5 years.
In the first paragraph of the discussion, the authors reported '81% rate in polyp eradication at 1 year'. 1 However, this term is also used in the abstract, where it is stated that '20.2% (15/74) cases achieved polyp eradication on angiogram', whereas 60.8% 'achieved polyp size reduction'. 1 Thus, the statement in the discussion may be misleading to some readers, who may infer 'eradication' to mean total closure of the polyps, which actually occurred in only 20.2% of cases. We are curious to know how the authors determined a decrease in size of the polyps. Was this based on the total area of all polyps and, if so, what was the minimum decrease in area required? Polyp closure is an important consideration in the management of PCV because some patients may suffer massive hemorrhages, with severe loss of vision. 5 In summary, we congratulate the authors on describing the risk factors for PCV outcomes, which highlights the need to consider various categories and subtypes of this disease.
